130 related articles for article (PubMed ID: 6341772)
1. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.
Chesnut CH; Ivey JL; Gruber HE; Matthews M; Nelp WB; Sisom K; Baylink DJ
Metabolism; 1983 Jun; 32(6):571-80. PubMed ID: 6341772
[TBL] [Abstract][Full Text] [Related]
2. The role of skeletal calcium deficiency in postmenopausal osteoporosis.
Burnell JM; Baylink DJ; Chesnut CH; Teubner EJ
Calcif Tissue Int; 1986 Apr; 38(4):187-92. PubMed ID: 3085896
[TBL] [Abstract][Full Text] [Related]
3. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
Chesnut CH; Nelp WB; Baylink DJ; Denney JD
Metabolism; 1977 Mar; 26(3):267-77. PubMed ID: 319322
[TBL] [Abstract][Full Text] [Related]
4. Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface.
Benéton MN; Yates AJ; Rogers S; McCloskey EV; Kanis JA
Clin Sci (Lond); 1991 Oct; 81(4):543-9. PubMed ID: 1657503
[TBL] [Abstract][Full Text] [Related]
5. Effect of calcium and stanozolol on calcitonin secretion in patients with femoral neck fracture.
Beringer TR; Ardill J; Taggart HM
Bone Miner; 1986 Sep; 1(4):289-95. PubMed ID: 3333017
[TBL] [Abstract][Full Text] [Related]
6. Relationship between local and total bone mass in osteoporosis.
Manzke E; Chesnut CH; Wergedal JE; Baylink DJ; Nelp WB
Metabolism; 1975 May; 24(5):605-15. PubMed ID: 1128230
[TBL] [Abstract][Full Text] [Related]
7. Calcitriol treatment is not effective in postmenopausal osteoporosis.
Ott SM; Chesnut CH
Ann Intern Med; 1989 Feb; 110(4):267-74. PubMed ID: 2913914
[TBL] [Abstract][Full Text] [Related]
8. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis.
Taggart HM; Applebaum-Bowden D; Haffner S; Warnick GR; Cheung MC; Albers JJ; Chestnut CH; Hazzard WR
Metabolism; 1982 Nov; 31(11):1147-52. PubMed ID: 6813637
[TBL] [Abstract][Full Text] [Related]
9. Skeletal mass in postmenopausal women.
Aloia JF; Cohn SH; Ross P; Vaswani A; Abesamis C; Ellis K; Zanzi I
Am J Physiol; 1978 Jul; 235(1):E82-7. PubMed ID: 677313
[TBL] [Abstract][Full Text] [Related]
10. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial.
Carson P; Hong CJ; Otero-Vinas M; Arsenault EF; Falanga V
Int J Low Extrem Wounds; 2015 Mar; 14(1):11-8. PubMed ID: 25652757
[TBL] [Abstract][Full Text] [Related]
11. Placebo therapy for postmenopausal osteoporosis.
Elias C; Heaney RP; Recker RR
Calcif Tissue Int; 1985 Jan; 37(1):6-13. PubMed ID: 3922599
[TBL] [Abstract][Full Text] [Related]
12. Long-term calcitonin therapy in postmenopausal osteoporosis.
Gruber HE; Ivey JL; Baylink DJ; Matthews M; Nelp WB; Sisom K; Chesnut CH
Metabolism; 1984 Apr; 33(4):295-303. PubMed ID: 6423929
[TBL] [Abstract][Full Text] [Related]
13. Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis.
Chesnut CH; Baylink DJ; Sisom K; Nelp WB; Roos BA
Metabolism; 1980 Jun; 29(6):559-62. PubMed ID: 7382823
[TBL] [Abstract][Full Text] [Related]
14. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
[TBL] [Abstract][Full Text] [Related]
15. Effects of stanozolol on bone mineral density and bone biomechanical properties of osteoporotic rats.
Liao JM; Wu T; Li QN; Hu B; Huang LF; Li ZH; Yuan L; Zhong SZ
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1117-20. PubMed ID: 14625163
[TBL] [Abstract][Full Text] [Related]
16. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
[TBL] [Abstract][Full Text] [Related]
18. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
19. Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients.
Yasumura S; Aloia JF; Gundberg CM; Yeh J; Vaswani AN; Yuen K; Lo Monte AF; Ellis KJ; Cohn SH
J Clin Endocrinol Metab; 1987 Apr; 64(4):681-5. PubMed ID: 3493257
[TBL] [Abstract][Full Text] [Related]
20. Total body calcium by neutron activation analysis in normals and osteoporotic populations: a discriminator of significant bone mass loss.
Ott SM; Murano R; Lewellen TK; Nelp WB; Chesnut CM
J Lab Clin Med; 1983 Oct; 102(4):637-45. PubMed ID: 6619649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
